Author Archives: Patricia Silva PhD

PAH Therapy Macitentan Proven Effective In Recent SERAPHIN Study

A novel dual endothelin receptor antagonist (ERA), Macitentan, (manufactured by Actelion pharmaceuticals) had been approved for use against Pulmonary Arterial Hypertension (PAH) by the US FDA in October 2013. This came shortly after Actelion Pharma presented the results of its landmark clinical trial SERAPHIN (Study with Endothelin Receptor Antagonist…

Pulmonary Arterial Hypertension Effectively Treated Using Sildenafil

Hypoxia is the clinical manifestation of loss of oxygen supply in the body, leading to difficulty in breathing. Alveolar hypoxia can cause constriction of the distal pulmonary arterioles, which leads to increased arterial pressure and pulmonary arterial hypertension (PAH). This is a common condition among people living in high altitudes,…

Low-Dose Radiation Leads To Drop In PAR For Idiopathic Pulmonary Arterial Hypertension Patient, According To Study

A novel concept of targeting the autonomic nervous system around pulmonary arteries and activation of vasointestinal peptides (VIP) to treat Idiopathic Pulmonary Arterial Hypertension (IPAH) was recently developed by a group of researchers. The study, published in the online journal Therapeutics and Clinical Risk Management (March 27, 2014), profiled a 58…